Experience with nanobodies taken from a llama named Cormac suggest the potential to prevent infections and prevent the transmission of the virus, Dr. David Brody, PhD, director of the Center for Neuroscience and Regenerative Medicine at the Uniformed Services University of the Health Sciences in Bethesda, Md, reported.

One nanobody, dubbed as NIH-CoVnb-112, worked in liquid and aerosol forms and was effective after inhalation, researchers reported. Low levels of the NIH-CoVnb-112 nanobodies prevented infection in in vitro studies, they reported.

2020 Golden Goose awards honor federally funded scientists in COVID-19
This years' winners of the Golden Goose awards recognizing federally funded research made contributions that promise to ease the COVID-19 pandemic.

Synthetic nanobodies show potential for new COVID-19 therapies
Synthetic nanobodies may provide a practical avenue for the development of novel COVID-19 therapies compared to human antibodies, which are bulkier and...

NIH initiates ACTIV trial for COVID-19 immune modulators
The U.S. National Institutes of Health (NIH) has launched an adaptive phase III trial called Accelerating COVID-19 Therapeutic Interventions and Vaccines...

National Institutes of Health launches 4th phase III COVID-19 vaccine study
A phase III clinical trial evaluating the investigational Janssen COVID-19 vaccine Ad26.COV2.S for the prevention of symptomatic COVID-19 in a single-dose...